


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-31. (Canceled)

32. (Currently Amended) A [[The]] method according to claim 24 of inhibiting respiratory burst in adherent neutrophils without inhibiting neutrophil degranulation in or bacterial killing by neutrophils, said method comprising: contacting adherent neutrophils with an effective amount of a chemical compound, wherein the compound has the formula:




wherein:

R¹ is substituted or unsubstituted phenyl;

R² is C₁-C₄ alkyl; and


R³ is substituted or unsubstituted quinoline with or without a linking group.

33. (Currently Amended) The method according to claim 32, wherein the compound has the formula:



.[[.]]

34. (Currently Amended) A [[The]] method according to claim 24 of inhibiting respiratory burst in adherent neutrophils without inhibiting neutrophil degranulation in or bacterial killing by neutrophils, said method comprising: contacting adherent neutrophils with an effective amount of a chemical compound, wherein the compound has the formula:




wherein:

R¹ is substituted or unsubstituted phenyl;


R² is C₁-C₄ alkyl; and

R³ is substituted or unsubstituted benzoylhydrazino.


35. (Original) The method according to claim 34, wherein the compound has the formula:




36. (Original) The method according to claim 34, wherein the compound has the formula:




37. (Original) The method according to claim 34, wherein the compound has the formula:




38. (Original) The method according to claim 34, wherein the compound has the formula:




39. (Original) The method according to claim 34, wherein the compound has the formula:



40. (Original) The method according to claim 34, wherein the compound has the formula:



41. (Original) The method according to claim 34, wherein the compound has the formula:



42. (Currently Amended) The method according to claim 32[[24]], wherein said contacting neutrophils is carried out *in vitro*.

43. (Currently Amended) The method according to claim 32[[24]], wherein said contacting neutrophils is carried out *in vivo*.

44. (Currently Amended) The method according to claim 32[[24]], wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by an agent selected from the group consisting of a chemokine, a cytokine, bacteria, and a bacterial factor.

45. (Withdrawn) The method according to claim 44, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a chemokine selected from the group consisting of macrophage inflammatory protein-1 (MIP-1), interleukin-8 (IL-8), and chemoattractant complement component C5a.

46. (Original) The method according to claim 44, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a cytokine selected from the group consisting of tumor necrosis factor (TNF), lymphotoxin, granulocyte-specific colony stimulating factor (G-CSF), and granulocyte/macrophage-specific colony stimulating factor (GM-CSF).

47. (Withdrawn) The method according to claim 44, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by bacteria selected from the group consisting of whole bacteria, bacterial cell wall components, and secreted or shed bacterial products.

48. (Withdrawn) The method according to claim 44, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a bacterial factor that is a soluble bacterial complement protein.

49. (New) The method according to claim 34, wherein said contacting neutrophils is carried out *in vitro*.

50. (New) The method according to claim 34, wherein said contacting neutrophils is carried out *in vivo*.

51. (New) The method according to claim 34, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by an agent selected from the group consisting of a chemokine, a cytokine, bacteria, and a bacterial factor.

52. (New) The method according to claim 51, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a chemokine selected from the group consisting of macrophage inflammatory protein-1 (MIP-1), interleukin-8 (IL-8), and chemoattractant complement component C5a.

53. (New) The method according to claim 51, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a cytokine selected from the group consisting of tumor necrosis factor (TNF), lymphotoxin, granulocyte-specific colony stimulating factor (G-CSF), and granulocyte/macrophage-specific colony stimulating factor (GM-CSF).

54. (New) The method according to claim 51, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by bacteria selected from the group consisting of whole bacteria, bacterial cell wall components, and secreted or shed bacterial products.

55. (New) The method according to claim 51, wherein said contacting with a compound inhibits respiratory burst in adherent neutrophils triggered by a bacterial factor that is a soluble bacterial complement protein.